4XB Stock Chart & Stats
€1.82
-€0.03(-1.41%)
At close: 4:00 PM EDT
€1.82
-€0.03(-1.41%)
Day’s Range― - ―
52-Week Range€1.69 - €2.86
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€58.95M
Enterprise Value-€43.20M
Total Cash (Recent Filing)€115.46M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.12
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.32
Shares Outstanding30,487,732
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)0.52
Price to Sales (P/S)0.00
P/FCF Ratio-1.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
XBiotech News
4XB FAQ
What was XBiotech’s price range in the past 12 months?
XBiotech lowest stock price was €1.69 and its highest was €2.86 in the past 12 months.
What is XBiotech’s market cap?
XBiotech’s market cap is €58.95M.
When is XBiotech’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were XBiotech’s earnings last quarter?
XBiotech released its earnings results on Mar 14, 2019. The company reported -€0.148 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.148.
Is XBiotech overvalued?
According to Wall Street analysts XBiotech’s price is currently Overvalued.
Does XBiotech pay dividends?
XBiotech does not currently pay dividends.
What is XBiotech’s EPS estimate?
XBiotech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does XBiotech have?
XBiotech has 30,487,732 shares outstanding.
What happened to XBiotech’s price movement after its last earnings report?
XBiotech reported an EPS of -€0.148 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of XBiotech?
Currently, no hedge funds are holding shares in DE:4XB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
XBiotech Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.60%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-23.11%
Trailing 12-Months
Company Description
XBiotech
XBiotech Inc. is a biopharmaceutical firm specializing in the discovery, development, and commercialization of True Human monoclonal antibodies. Their primary focus involves building a robust pipeline of product candidates aimed at combating both inflammatory and infectious diseases. Furthermore, the company is advancing interleukin-1 alpha-based therapies, which are designed to address a broad spectrum of medical conditions such as cancer, stroke, heart attack, and arthritis. Interleukin-1 alpha itself plays a crucial role in biological processes like tissue breakdown, angiogenesis, blood clot formation, malaise, muscle wasting, and inflammation. Additionally, XBiotech is developing a True Human COVID-19 therapy specifically targeting mutant strains of the virus. Established in 2005, XBiotech Inc. maintains its headquarters in Austin, Texas.
Technical Analysis
Atara Biotherapeutics
―
Adicet Bio
―
Elicio Therapeutics
―
TScan Therapeutics
―
Xilio Therapeutics
―